Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

The NDA follows positive results from the Phase III global placebo-controlled, randomised VERIFY trial.

Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...